cardiac glycosides are thought to prevent doxorubicin cardiomyopathy by competitively inhibiting doxorubicin at its receptor sites , but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin .
C0007158
cardiac glycosides
C0012265
digoxin